Inimmune’s focus is to discover and develop novel innate immune modulating compounds for treatment of a host of immune diseases. Currently the company’s pipeline is focused on utilizing several late stage Toll-like receptor (TLR) agonists and antagonists for use in food allergy, allergic rhinitis and auto-immunity. Next generation projects will focus on developing these agents for use in topical skin cancer and development on novel bi-functional chemo-immunotherapeutics for solid tumor treatment.
Inimmune’s first objective is to develop a next generation food allergy vaccine to treat patients with both moderate and severe food allergy. There are no currently approved prophylactic treatments for many food allergies. Inimmune’s lead candidate food allergy vaccine is currently in late-stage preclinical studies and will be advancing to clinical toxicity studies in late 2016. The vaccine will be administered sublingually (under the tongue).
Inimmune is investigating utilization of their novel innate immune receptor agonists to induce allergen independent and/or dependent immune-system modulation for the treatment of allergic rhinitis as a result of seasonal allergies.
Inimmune is investigating the use of our TLR agonists/antagonists to alter the induction of Th1/Th2/Th17-mediated autoimmune diseases. Programs are currently in early discovery phase.
Upper Respiratory Tract Infections
Inimmune is developing immunomodulators to induce broad antiviral innate immunity for the reduction of viral URT and associated exacerbations in asthma and COPD patients.
Inimmune is developing several innate immune modulators and bi-functional chemo-immunotherapy agents for the treatment of various cancers.
Copyright © 2015 Inimmune